Venous thrombotic disease
Conditions
Interventions
Experimental Group:Anticoagulant combined with Micronized Purified Flavonoid Fraction (MPFF)
Sponsors
Shanxi Bethune Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age >=20 years old and =72 hours; 3. DVT within one month accompanied by obvious lower extremity symptoms such as swelling; 4. Sign a written informed consent (signed by the patient themselves or their legal guardian); 5. Good organ function, including but not limited to: (1) Good liver function, good kidney function and good cardiopulmonary function; (2) Good bone marrow function: hemoglobin (Hb) >=80g/L, platelet (PLT) >=100×10^9/L; 6. During the visit, conservative treatment is evaluated by a professional doctor or strongly wishes to be carried out by the patient and their family. No surgical treatment was performed during the later follow-up period.
Exclusion criteria
Exclusion criteria: 1. Patients with acute thrombosis who require surgical intervention to improve clinical symptoms; 2. Secondary conditions may occur due to tumors, trauma, etc. 3. DVT patients with venous injury; 4. There are severe liver or kidney function diseases; In the pregnancy or lactation period; 5. People who are allergic to intravenous active drug components such as citrus flavonoids; 6. Have participated in similar trials or are currently undergoing other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| D-dimer;Blood cell analysis;CRP;Villalta rating;Quality of Life scoring sheet;Recurrence of thrombosis;Post-thrombotic syndrome;Death; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index; | — |
Countries
China
Contacts
Public ContactTao Yang
Shanxi Bethune Hospital
Outcome results
None listed